Status:
COMPLETED
Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years at index date
- Prescription of mavacamten for the treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM)
- ≥ 4 weeks of follow-up after prescription of mavacamten
Exclusion
- Data collection as part of a clinical trial during the study period
- Current participation in a myosin inhibitor clinical trial
Key Trial Info
Start Date :
February 21 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 25 2025
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT07168655
Start Date
February 21 2023
End Date
March 25 2025
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104